Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

ARD-101

Small molecule · developed by Aardvark Therapeutics

Phase 3 Most advanced trial (none active)

AARD Developer

1 Registered trials

What is ARD-101?

ARD-101 is an investigational small-molecule drug studied in Hyperphagia, Prader-Willi Syndrome, Hyperphagia in Prader-Willi Syndrome.

At a glance

Drug type: Small molecule
Therapy area: Neurology
Developer: Aardvark Therapeutics, Inc. (AARD)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 3
UNII: YE84H43CRF

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT07197034	Phase 3	Hyperphagia	Terminated	AARD

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

HyperphagiaHyperphagia in Prader-Willi SyndromePrader-Willi Syndrome

More from Aardvark Therapeutics

ARD-501 Phase 2

Sources

ClinicalTrials.gov NCT07197034

Updated Oct 3, 2026. Something wrong or missing? Report it on the AARD page.

Follow AARD, the company behind ARD-101

See AARD's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

AARD catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z